Observational studyImmunity, inflammation and disease2025
Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV-Infected Individuals in Southwest China: A Retrospective Observation Study.
Observational study in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV-Infected Individuals in Southwest China: A Retrospective Observation Study.Immunity, inflammation and disease · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term outcome data from real-world studies of the bictegravir emtricitabine tenofovir alafenamide fumarate (B/F/TAF) regimen in the treatment of elderly patients with HIV/AIDS are still limited. This study evaluated the real-world effectiveness and safety of B/F/TAF in elderly HIV-infected individuals in southwest China.
methodsThis was an observational, single-center, retrospective study that enrolled antiretroviral therapy (ART)-naïve (n = 149) and ART-experienced (n = 143) patients with HIV infection between January 2021 and April 2024. The main endpoint was the viral suppression rate of HIV RNA < 50 copies/ml at 48 weeks, and change in CD4 cell count, CD4/CD8 ratio, body weight, blood lipid and safety were secondary endpoints.
resultsThe proportions of ART-naïve and ART-experienced HIV-infected cases with VL < 50 copies/mL at 48 weeks were 93.1% and 92.9%, respectively. CD4 cell counts and CD4/CD8 ratios increased significantly from baseline at 48 weeks (p < 0.001). In the treatment-naive group, ALT, AST, eGFR, and Glu decreased significantly from baseline at 48 weeks, while body weight, Scr, TC, HDL, and LDL increased significantly. Among patients previously administered ART, eGFR increased significantly from baseline at 48 weeks, while AST, LDL, and Scr decreased significantly; other indicators showed no significant changes from baseline. The incidence rates of adverse events were 11.7% and 4.3% in treatment-naïve and treatment-experienced, respectively.
conclusionsFor elderly HIV/AIDS patients, B/F/TAF is a safe option to achieve and maintain virological suppression and immune recovery. In terms of lipid metabolism, the metabolic effects of BIC/FTC/TAF in the treated patients are not significant, and the effects in untreated patients require longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.